Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.

Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A

Open source

DOI: 10.1001/jamanetworkopen.2020.20425
Published: 2020 Oct 1
Container: JAMA network open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamanetworkopen.2020.20425,
  title = {Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.},
  author = {Chibaudel B and Henriques J and Rakez M and Brenner B and Kim TW and Martinez-Villacampa M and Gallego-Plazas J and Cervantes A and Shim K and Jonker D and Guerin-Meyer V and Mineur L and Banzi C and Dewdney A and Dejthevaporn T and Bloemendal HJ and Roth A and Moehler M and Aranda E and Van Cutsem E and Tabernero J and Schmoll HJ and Hoff PM and André T and de Gramont A},
  year = {2020},
  journal = {JAMA network open},
  doi = {10.1001/jamanetworkopen.2020.20425},
  url = {https://doi.org/10.1001/jamanetworkopen.2020.20425}
}

RIS

TY  - JOUR
TI  - Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
AU  - Chibaudel B
AU  - Henriques J
AU  - Rakez M
AU  - Brenner B
AU  - Kim TW
AU  - Martinez-Villacampa M
AU  - Gallego-Plazas J
AU  - Cervantes A
AU  - Shim K
AU  - Jonker D
AU  - Guerin-Meyer V
AU  - Mineur L
AU  - Banzi C
AU  - Dewdney A
AU  - Dejthevaporn T
AU  - Bloemendal HJ
AU  - Roth A
AU  - Moehler M
AU  - Aranda E
AU  - Van Cutsem E
AU  - Tabernero J
AU  - Schmoll HJ
AU  - Hoff PM
AU  - André T
AU  - de Gramont A
PY  - 2020
JO  - JAMA network open
DO  - 10.1001/jamanetworkopen.2020.20425
UR  - https://doi.org/10.1001/jamanetworkopen.2020.20425
ER  -

APA

B, C., J, H., M, R., B, B., TW, K., M, M., J, G., A, C., K, S., D, J., V, G., L, M., C, B., A, D., T, D., HJ, B., A, R., M, M., E, A., E, V. C., J, T., HJ, S., PM, H., T, A., & A, D. G. (2020). Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2020.20425

Source records

pubmed · retrieved 2026-09-27T01:23:30.563Z
europe-pmc · retrieved 2026-09-27T01:23:30.497Z